| Name | Mexiletine hydrochloride |
| Description | Mexiletine hydrochloride (KOE-1173 hydrochloride) is a voltage-gated sodium channel blocker and a Class IB antiarrhythmic drug. Mexiletine hydrochloride exerts antiarrhythmic effects by inhibiting sodium current in myocardial cells, thereby reducing the rise rate of cardiac action potential (phase 0) and reducing the automaticity of Purkinje fibers. |
| In vitro | Mexiletine shortened the cardiac Purkinje fiber effective response period (ERP) less than the action potential duration (APD), resulting in higher ERP/APD ratios.Mexiletine had no significant effect on atrioventricular conduction velocity, resting membrane potential, sinus node autoregulation, systolic arterial pressure, left ventricular function, or QRS or QT intervals. Mexiletine inhibits the inward flow of sodium ions through inhibition of sodium channels (requiring pulse initiation and conduction), which in turn reduces the rate of action potential elevation. |
| In vivo | Mexiletine shortened the cardiac Purkinje fiber effective response period (ERP) less than the action potential duration (APD), resulting in higher ERP/APD ratios.Mexiletine had no significant effect on atrioventricular conduction velocity, resting membrane potential, sinus node autoregulation, systolic arterial pressure, left ventricular function, or QRS or QT intervals. Mexiletine inhibits the inward flow of sodium ions through inhibition of sodium channels (requiring pulse initiation and conduction), which in turn reduces the rate of action potential elevation. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (9.27 mM), Sonication is recommended.
DMSO : 50 mg/mL (231.78 mM), Sonication is recommended.
H2O : 21.6 mg/mL (100.13 mM), Sonication is recommended.
|
| Keywords | Voltage-gated sodium channel | SodiumChannel | Sodium Channel | Na+ channels | Na channels | myocardial | Mexiletine hydrochloride | Mexiletine | KOE-1173 | KOE1173 | KOE 1173 | KO-1173 | KO 1173 | ischemia | Inhibitor | inhibit | Class IB | antiarrhythmic | AhR |
| Inhibitors Related | Phenytoin sodium | Procaine | Ranolazine dihydrochloride | Tetracaine hydrochloride | Lidocaine | Safinamide | Permethrin | Valproic Acid | L-Aspartic aicd sodium | Lidocaine hydrochloride | Mebeverine hydrochloride | Skatole |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
United States
